FluoroPharma Medical, developer of breakthrough molecular imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of pathology before clinical manifestation of diseases, announced this morning the release of a company overview as presented by FluoroPharma’s … Continue reading →

FluoroPharma Medical, a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, today after the closing bell announced that it has appointed … Continue reading →

It’s hard to imagine a successful company without a board of directors that is insightful, responsible, and comfortable with any technologies involved in the company’s products or operations. A board is, after all, generally responsible for formulating and establishing broad … Continue reading →

FluoroPharma, a developer of advanced tracing chemicals used with positron emission tomography (PET) to help detect heart disease and other problems, recently received a positive report from Life Tech Capital Institutional Research. The points emphasized on top of the report … Continue reading →

FluoroPharma, a developer of specialized molecular imaging pharmaceuticals used with positron emission tomography (PET) to help detect heart disease and other problems, has stated that it intends to develop its products through the completion of phase II and/or phase III … Continue reading →

FluoroPharma Medical, Massachusetts-based developer of advanced imaging pharmaceuticals for use with positron emission tomography (PET), intends to become the leader in the early detection of coronary artery and alzheimer diseases, two of the most high-profile diseases in the country. Through … Continue reading →

FluoroPharma Medical is a developer of unique, targeted molecular imaging pharmaceuticals used with positron emission tomography (PET). Although the company is focused primarily on the detection of cardiovascular disease (CAD) related processes, the company has other imaging agents in the … Continue reading →

FluoroPharma Medical intends to lead in the discovery, development, and commercialization of innovative and targeted molecular imaging pharmaceuticals that improve disease detection, management, and overall patient care. The company’s focus has been chemical tracer agents that are used in conjunction … Continue reading →

In the marketplace, the principal strength of FluoroPharma Medical, developer of tracer agents for use with positron emission tomography (PET), is the uniqueness and effectiveness of their products. Their chemical agents, by highlighting certain biological processes in the body, allow … Continue reading →

FluoroPharma Medical, a developer of imaging agents for use with positron emission tomography (PET) scanning, helps to make visible subtle biological processes occurring deep within the body. From its founding in 2003, with technology licensed from Massachusetts General Hospital, the … Continue reading →